Financial Crossroads | Splash Beverage Group faces critical challenges with weak financial health, yet shows potential for turnaround through new funding and strategic initiatives |
Acquisition Ambitions | Explore SBEV's plans to acquire Western Son Vodka, a move expected to boost revenue and operational efficiencies, reshaping the company's market position |
Analyst Outlook | H.C. Wainwright & Co. maintains a Buy rating with a $1.00 price target, reflecting cautious optimism amid SBEV's transformation efforts |
Growth Projections | Delve into SBEV's ambitious targets: $38-40 million revenue by 2025 with positive EBITDA, contingent on successful strategy execution and market dynamics |
Metrics to compare | EDVA | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipEDVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −0.8x | 11.3x | |
PEG Ratio | 0.00 | 0.02 | 0.03 | |
Price/Book | −0.1x | 4.3x | 1.5x | |
Price / LTM Sales | 49.8x | 1.8x | 0.9x | |
Upside (Analyst Target) | - | 60.0% | 25.6% | |
Fair Value Upside | Unlock | 2.0% | 13.6% | Unlock |
Endovia Health Sciences, Inc. develops a diversified cannabinoid health sciences platform that translates science into regulated therapies and trusted health and wellness products for people and animals in Ireland, United Kingdom, Australia, and Latin America. Its product includes CannEpil a pharmaceutical-grade cannabinoid formulation comprising cannabidiol and tetrahydrocannabinol isolates in an oral liquid solution. Endovia Health Sciences, Inc. formerly known as Splash Beverage Group, Inc. The company is based in Fort Lauderdale, Florida.